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Background: The aim of the study was to investigate the efﬁcacy and safety of ciclesonide
compared with budesonide in adolescents with severe asthma.
Methods: In this randomized, double-blind, double-dummy, parallel-group study, patients
aged 12–17 years with severe asthma were treated with budesonide 400 mg once daily (QD)
in a 2-week run-in period. At randomization, eligible patients were assigned 2:1 to
ciclesonide 320 mg QD (ex-actuator) or budesonide 800 mg QD (metered dose), respectively,
in the evening. Forced expiratory volume in 1 s (FEV1) was the primary variable. Patients
recorded asthma symptom score and rescue medication use in diaries. Safety assessments
included adverse events (AEs) and 24-h urine cortisol.
Results: Four hundred and three patients were randomized. Ciclesonide 320 mg QD and
budesonide 800 mg QD signiﬁcantly increased FEV1 (least-squares mean: 505 and 536mL,
respectively; both po0.0001 versus baseline) in the intention-to-treat (ITT) population.
Lower limits of the 95% conﬁdence intervals (ITT: 138mL; per-protocol: 122mL) were
above the non-inferiority limit (150mL). Median percentage of days without asthma
symptoms and without rescue medication use was 84% with ciclesonide and 85% with
budesonide. AEs were unremarkable, with no cases of conﬁrmed candidiasis. Median
creatinine-adjusted urine cortisol signiﬁcantly decreased with budesonide treatment
(15.9–13.7 nmol cortisol/mmol creatinine; p ¼ 0.0086 versus baseline), but not with
ciclesonide (p ¼ 0.1125).Elsevier Ltd. All rights reserved.
300634; fax: +27 21 9300662.
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Ciclesonide and budesonide in adolescent asthma 2183Conclusions: Ciclesonide 320 mg QD showed similar efﬁcacy to budesonide 800 mg QD in
adolescents with severe asthma. Ciclesonide was well tolerated and, unlike budesonide,
had no effect on urine cortisol levels.
Clinical trial registration number: EudraCT No.: 2004-001233-41.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic inﬂammatory disorder of the airways
deﬁned by hyper-responsiveness and variable airﬂow ob-
struction. Approximately 300 million people suffer from the
disease worldwide, although differences exist between
countries,1–3 and its prevalence is rising. By 2025, it is
estimated that an additional 100 million individuals will
be diagnosed with asthma.4 Goals of treatment are to
provide effective management and long-term control of
asthma, with minimal impact from symptoms or adverse
events (AEs). Currently, a number of therapeutic agents
exist for the management of asthma, of which, national
and international guidelines recommend the use of inhaled
corticosteroids (ICS) as the ﬁrst-line therapy for persis-
tent asthma of all severities in adults, adolescents and
children.5,6
Several different ICS are available. They are character-
ized by high local anti-inﬂammatory activity, resulting in
reductions in asthma symptoms and acute exacerbation
frequency, decreases in the need for rescue medications and
improvements in airway patency and hyper-responsiveness.7
Regular use of ICS is supported by pathophysiologic ﬁndings
and efﬁcacy data; however, safety issues remain a concern
regarding local or systemic AEs at high doses, such as
adrenal suppression and reductions in bone density.7,8 An ICS
should, therefore, be used at the lowest possible dose that
prevents symptoms and eliminates the need for supple-
mental courses of oral glucocorticoids.7,8
Ciclesonide (Alvescos, ALTANA Pharma) is a novel ICS for
the treatment of persistent asthma that is administered via
a metered-dose inhaler (MDI) using hydroﬂuoroalkane 134a
(HFA-134a) as the propellant. This formulation generates a
high fraction of ﬁne particles enabling high lung deposition
of more than 50% of the delivered dose and greater
accessibility of the drug to the small airways of the
respiratory system.9 After inhalation, the inactive prodrug,
ciclesonide, is converted to its active metabolite, desiso-
butyryl ciclesonide, in the lung by airway esterases.10
Therefore, the amount of the active metabolite of cicleso-
nide in the oropharynx is negligible,11,12 resulting in a low
potential for oral AEs.13 Furthermore, because ciclesonide is
rapidly metabolized to inactive metabolites in the liver,
systemic exposure is minimized.10 In addition, ciclesonide is
highly protein bound (approximately 99%), which may also
reduce systemic exposure.14
The efﬁcacy of ciclesonide in adults and children has been
demonstrated in a number of clinical studies, alongside a
favorable systemic safety proﬁle.15–20 However, to date,
limited data are available regarding the efﬁcacy and safety
of ciclesonide in adolescent patients. This study is the ﬁrst
to be performed exclusively in adolescent patients withsevere asthma to investigate the efﬁcacy and safety of
ciclesonide compared with budesonide.
Methods
Subjects
Male and female out-patients aged 12–17 years with a
history of asthma, according to the Global Initiative for
Asthma (GINA) 2003 classiﬁcation, for X6 months, but
otherwise in good health, were eligible for inclusion in a 2-
week run-in period prior to randomization. Patients not well
controlled after constant treatment with a ﬁxed dose of
budesonide 400 mg/day (or equivalent) forX4 weeks prior to
study entry with a forced expiratory volume in 1 s (FEV1)
450% to o80% of that predicted were included. Alterna-
tively, patients had to have been constantly treated with a
ﬁxed dose of budesonide 4400 to p800 mg/day (or
equivalent) for X4 weeks prior to study entry and have an
FEV1 460% to o85% of predicted. For entry into the
treatment period at randomization (baseline), patients had
to have an FEV1450% too80% of predicted and a reversible
obstruction of DFEV1 X15% of initial, after inhalation of
salbutamol. Patients with concomitant severe diseases,
relevant lung diseases or clinically relevant abnormal
laboratory values, ex- or current smokers with X10
cigarette pack-years and those using systemic steroids
within 2 months prior to run-in were excluded. Female
patients of child-bearing potential were excluded if they
were not using safe contraception.
Written informed consent was obtained from patients and
their parent(s) or legal guardian(s) prior to the study, and
the protocol was approved by the appropriate regional
Institutional Review Boards or Independent Ethics Commit-
tees. The study was conducted in accordance with the
ethical principles of the Declaration of Helsinki 199621 and
the rules of the International Conference on Harmonization
Good Clinical Practice consolidated guideline.
Study design
The study was performed in 31 centers in Hungary, Poland,
Serbia/Montenegro, South Africa and Spain, and had a
randomized, double-blind, double-dummy, parallel-group
design consisting of a 2-week run-in period and a 12-week
treatment period. During run-in, patients were treated with
budesonide 400 mg (two inhalations of 200 mg from the
Turbohalers [TH] device) once daily in the evening to
standardize treatment on the same dose level as the 4
weeks prior to study entry. Patients who met the entry
criteria for the treatment period were randomly assigned
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actuator corresponding to two puffs of 200 mg ex-valve from
MDIs)1 or once-daily budesonide 800 mg (four inhalations of
200 mg from the TH device), respectively, both administered
in the evening. Blinding was achieved by providing patients
with an MDI containing either ciclesonide or ciclesonide
placebo, and a TH containing either budesonide or budeso-
nide placebo. Salbutamol 100 mg/puff was used as rescue
medication throughout the study, as necessary.
The randomization list was generated by the sponsor using
a multiplicative congruential pseudo-random number gen-
erator with modulus 231-1 (Program RANDOM based on
Fishman and Moore.22 Patients who qualiﬁed for the study
were assigned a number in chronological order beginning
with the lowest number available for the study center.Efﬁcacy measures
At each study visit (weeks 0, 4, 8 and 12), FEV1, forced vital
capacity (FVC) and peak expiratory ﬂow (PEF) were
recorded. Individual spirograms were checked for accept-
ability and reproducibility according to American Thoracic
Society recommendations.23 The same spirometry equip-
ment was to be used throughout the study at each site and
the same person performed the measurements, where
possible. All lung function tests were performed before
the evening administration of study medication and 412 h
after the last use of study medication and at least 4 h after
last use of salbutamol. Patients recorded PEF, asthma
symptom score and rescue medication use (number of puffs)
in daily diaries. PEF was recorded by patients in the morning
and evening using a Vitalograph PEF meter, before inhala-
tion of study medication. For each measurement, three
readings were to be obtained in a standing position and all
three values were recorded; the highest value per series was
used for evaluation.
Asthma symptom scores were assessed using 5-point
scales (nighttime: 0 ¼ no asthma symptoms, slept through
the night to 4 ¼ bad night, awake most of the night because
of asthma; daytime: 0 ¼ very well, no asthma symptoms to
4 ¼ asthma very bad, unable to carry out daily activities as
usual). Patients experiencing an asthma exacerbation that
required additional asthma medication other than increased
use of rescue medication were withdrawn.
Asthma-speciﬁc quality of life (QoL) was assessed using
the standardized version of the Pediatric Asthma Quality of
Life Questionnaire (PAQLQ[S]), a disease-speciﬁc instrument
developed to measure physical, emotional and social
impairments troublesome to children and adolescents with
asthma aged 7–17 years.24,25 The questionnaire was self-
administered by patients at baseline and at week 12/study
end. Validated translations were supplied for all languages.
The PAQLQ(S) consists of 23 items allocated to three
domains—activity limitations, symptoms and emotional
function—and each question was answered using a 7-point
scale (1 ¼ maximal impairment to 7 ¼ no impairment).1The ex-valve dose is the dose released from the valve of the
delivery system, while the ex-actuator dose is the dose delivered
after excluding the drug deposited on the actuator of the delivery
system.Safety evaluations
Safety was assessed by AE reporting, vital signs (blood
pressure and heart rate), electrocardiogram (ECG) ﬁndings,
physical examination and clinical laboratory tests, including
24-h urine cortisol (Immulite, DPC Biotech) to determine the
effects of treatment on the hypothalamic–pituitary–adrenal
(HPA) axis. Cortisol was adjusted for creatinine to account
for potentially incomplete urine sampling. For the restricted
safety analysis, the corresponding creatinine levels had to
be within normal ranges and, in addition, baseline values
had to be taken before the ﬁrst intake of study medication
and within 24 h of the last study medication intake. The
occurrence of oral candidiasis was monitored and conﬁrmed
by culture.Statistical analyses
The primary variable was change in FEV1 from baseline to
the last recorded measurement, and the co-primary variable
was the percentage of days without any asthma symptoms
and without use of rescue medication. Secondary endpoints
were change in FEV1% of predicted, FVC and PEF (spirome-
try) from baseline to the last recorded measurement; the
difference between the average diary-recorded value during
the week before baseline and the last week of treatment for
changes in morning and evening PEF, total asthma symptom
scores and number of puffs of rescue medication/day;
percentage of rescue medication-free days and symptom-
free days/nights from diaries; percentage of patients
experiencing an asthma exacerbation and time to ﬁrst
asthma exacerbation (days); and change from baseline to
last measurement in overall score and separate domain
scores the PAQLQ(S).
To achieve a power of 90% for correctly concluding non-
inferiority (a ¼ 0.025, one-sided) for the primary variable,
300 patients were needed for the per-protocol (PP) analysis
(200 ciclesonide, 100 budesonide). Allowing for about 20% of
patients not qualifying, a sample size of 360 randomized
patients (240 ciclesonide, 120 budesonide) was required.
Tests for non-inferiority of ciclesonide to budesonide were
based on the PP analysis. Non-inferiority acceptance limits
were set to 150mL for FEV1, 150mL for FVC, 20 L/min
for PEF (spirometry) and morning and evening PEF (from
diary), 8% for percentage of days without any asthma
symptoms and without use of rescue medication, and 0.5
scores for the PAQLQ(S).
An analysis of covariance model following that suggested
by Ebbutt and Frith26 was used to test within- and between-
group differences for FEV1, FVC, PEF (spirometry), morning
and evening PEF (diary), and PAQLQ(S) scores. Baseline
value, treatment, age, sex and country pool were covariates
or factors. Non-parametric within-group comparisons of
asthma symptom scores, rescue medication use and urine
cortisol variables were performed using Pratt’s-modiﬁed
Wilcoxon’s signed-rank test. For each within-treatment
comparison, the Hodges–Lehman point-estimate, 95%
conﬁdence interval (CI) and respective two-sided p-value
were given. Non-parametric between-group comparisons of
percentage of days without any asthma symptoms and
without use of rescue medication, asthma symptom
scores, use of rescue medication, symptom-free days, rescue
medication-free days and nocturnal awakening-free days were
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point-estimates, 95% CIs and p-values (one-sided for superiority
and two-sided), were given.
Results
Demographic and baseline characteristics
Of 431 patients enrolled, 403 (93.5%) were randomized and
took at least one dose of study medication (ciclesonide,
n ¼ 272; budesonide, n ¼ 131) and formed the intention-to-
treat (ITT) population. Of these, 384 patients completed the
study (ciclesonide: 95.2%, n ¼ 259; budesonide: 95.4%,
n ¼ 125) (Fig. 1). The PP population consisted of 371
patients (ciclesonide: n ¼ 249; budesonide: n ¼ 122). Four
hundred and three patients were included in the safety
population.
The demographic and baseline characteristics of the
treatment groups were comparable for most parameters
(Table 1). Baseline data for the PP population were similar
to those for the ITT set. All patients (ITT and PP) had severe
persistent asthma according to the GINA 2003 classiﬁca-
tion,27 and all patients were non-smokers. The most
frequent previous and concomitant disease was allergic
rhinitis. In both treatment groups, over 50% of patients had
allergic rhinitis, approximately 9% had acute atopic con-
junctivitis and approximately 4% had atopic dermatitis.
Antihistamines and nasal corticosteroids were taken by
30–35% and 18–22% of patients, respectively, in both groups
during all phases of the study. Use of leukotriene antagonists
and/or theophylline was recorded in p3% of patients.
Lung function
There were signiﬁcant increases in FEV1 (least-squares
(LS) mean) from baseline to study end in the ciclesonideFigure 1 Flow diagram of patient deposition (CONSORT dia320 mg/day group (505mL) and the budesonide 800 mg/day
group (536mL) (both po0.0001 versus baseline) in the ITT
population. Similar results were seen in the PP population
(Table 2). The lower limit of the 95% CI for the between-
treatment difference was above the non-inferiority accep-
tance limit of 150mL for both ITT and PP analyses ( 138 and
122mL, respectively). In addition, there was no signiﬁcant
difference between the treatment groups. Signiﬁcant
increases in FEV1 were seen between baseline and each
subsequent study visit in both treatment groups (ITT: all
po0.0001). FEV1% predicted increased in the ciclesonide
group from 73.1% at baseline to 89.4% at study end, and
in the budesonide group from 73.0% to 90.7% (ITT analysis;
LS means); there was no signiﬁcant difference between
treatment groups. The time course for FEV1% predicted is
shown in Fig. 2. Findings were similar in the PP population.
In both treatment groups there was a signiﬁcant
(po0.0001) increase in FVC from baseline to study
end in the ITT analysis (Table 2), with larger increases in
the PP population. Between-treatment differences were
0.04070.061 L (LS mean7standard error of the mean
[SEM]; 95% CI: 0.159, 0.080) in the ITT analysis and
0.01370.059 L (95% CI: 0.129, 0.103) in the PP
analysis. PEF measured at the study centers signiﬁcantly
increased (po0.0001) during the study in both treatment
groups by a comparable degree (Table 2). The between-
treatment difference was 3.078.8 L/min (LS mean7SEM;
95%CI: 14.4, 20.4). Similar ﬁndings were seen in the PP
population.
Morning and evening PEF increased in both treatment
groups; in the ITT population, the increases were signiﬁcant
in the ciclesonide group for both morning and evening
assessments (p ¼ 0.0424 and 0.0263, respectively), but not
in the budesonide group (Table 2). The between-treatment
differences for both morning and evening PEF conﬁrmed the
non-inferiority of ciclesonide versus budesonide in both the
ITT and PP populations.gram). BUD, budesonide; CIC, ciclesonide; PM, evening.
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Table 1 Demographic and baseline disease characteristics in the intention-to-treat and per-protocol populations.
Variable ITT (n ¼ 403) PP (n ¼ 371)
Ciclesonide
320 mg once
daily (n ¼ 272)
Budesonide
800 mg once
daily (n ¼ 131)
Ciclesonide
320 mg once
daily (n ¼ 249)
Budesonide
800 mg once
daily (n ¼ 122)
Age (years) Median (range) 14.0 (12–17) 14.0 (12–17) 14.0 (12–17) 13.5 (12–17)
Sex
Male/female n (%) 192/80
(70.6/29.4)
80/51
(61.1/38.9)
180/69
(72.3/27.7)
74/48
(60.7/39.3)
Pre-treatment ICS
p500 mg/day BDP eq n (%) 197 (72.4) 93 (71.0) 182 (73.1) 88 (72.1)
4500 mg/day BDP eq n (%) 75 (27.6) 38 (29.0) 67 (26.9) 34 (27.9)
FEV1 (mL) Mean7SD 23427480 22497499 23317481 22427509
FEV1 (% predicted) Mean7SD 73.276.3 73.176.4 72.976.2 72.876.3
FEV1 reversibility
(% initial)
Mean7SD 21.9713.0 26.4716.5 22.1713.1 28.3715.8
ITT, intention to treat; PP, per protocol; n, number of patients; ICS, inhaled corticosteroid; BDP, beclomethasone dipropionate; eq,
equivalent; FEV1, forced expiratory volume in 1 s; SD, standard deviation.
J.H. Vermeulen et al.2186Asthma exacerbations were recorded in 2.6% (n ¼ 7) of
patients receiving ciclesonide and 1.5% (n ¼ 2) of patients
receiving budesonide in the ITT set, in line with the 2:1
randomization. There was no clinically relevant difference
between the ciclesonide and budesonide groups. For time to
ﬁrst asthma exacerbation, there was no statistically
signiﬁcant difference between treatments.
Asthma symptom scores and rescue medication
The co-primary endpoint (median percentage of days with-
out any asthma symptoms and without use of rescue
medication) was 84% in the ciclesonide group and 85% in
the budesonide group (both ITT and PP analyses). The lower
limit of the 95% CI for the between-treatment difference
was 1.4% in the ITT analysis and 2.5% in the PP analyses;
both were above the non-inferiority acceptance limit (8%).
Median asthma symptom scores were signiﬁcantly
(po0.05) reduced during the study in both treatment
groups in both the ITT and PP analyses (Table 3), and there
were no statistically signiﬁcant differences between treat-
ments. In the ITT population, median use of rescue
medication was reduced to zero puffs per day in the
ciclesonide and budesonide groups at study end. Symptom-
free days (%) and rescue medication-free days (%) for the ITT
analysis are shown in Fig. 3. The percentage of nocturnal
awakening-free days was 100% in both treatment groups.
Similar ﬁndings were seen for the PP population.
Quality of life
During the study, ciclesonide and budesonide signiﬁcantly
improved QoL overall, and the individual domains of
activities, symptoms and emotions, by a comparable amount
(all po0.05) (Table 3). The lower limit of the 95% CI of thebetween-treatment difference was above the non-inferior-
ity limit of 0.5 for all domains and the overall score in the
ITT population. Similar results were found in the PP
population.
Safety
Adverse events
Pharyngitis and asthma were the most frequently documen-
ted AEs (Table 4). The majority of AEs in both treatment
groups were mild or moderate in intensity. Very few patients
experienced AEs that were assessed by the investigators as
being likely related to study treatment (ciclesonide, 2
[0.7%]; budesonide, 1 [0.8%]) and no patients had AEs that
were assessed as being deﬁnitely related to study treat-
ment. No deaths were reported during the study and there
were no serious AEs related to study treatment. There were
no cases of conﬁrmed candidiasis during the study.
Laboratory evaluations and vital signs
For patients not using concomitant steroids, the median
values for 24-h urine cortisol adjusted for creatinine at
baseline were comparable for the two treatment groups.
Median urine cortisol signiﬁcantly decreased in the budeso-
nide group from baseline to study end (15.9–13.7 nmol cor-
tisol/mmol creatinine; p ¼ 0.0086). The change in the
ciclesonide group was not signiﬁcant (15.9–16.5 nmol corti-
sol/mmol creatinine; p ¼ 0.1125) (Fig. 4), while the
difference between treatment groups was signiﬁcant
(p ¼ 0.0012). The cortisol analyses in the overall safety
population showed similar results.
No general trend towards consistent changes in any other
laboratory parameters was apparent in either treatment
group and there were no relevant differences between
the treatment groups for these variables. Mean blood
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Table 2 Improvement in lung function after 12 weeks of treatment with either ciclesonide 320 mg once daily or budesonide
800 mg once daily.
Variable ITT PP
Ciclesonide 320 mg once
daily
BUD 800 mg once
daily
Ciclesonide 320 mg once
daily
BUD 800 mg once
daily
FEV1 (mL)
n 270 130 237 120
Baseline 2310 2310 2294 2294
Change from
baseline
505734 536745 518734 533745
p-value o0.0001 o0.0001 o0.0001 o0.0001
Change versus BUD 0.03170.054 – 0.01670.054 –
95% CI 0.138, 0.076 – 0.122, 0.091 –
FVC (L)
n 270 130 237 120
Baseline 2.955 2.955 2.915 2.915
Change from
baseline
0.43370.037 0.47270.051 0.50170.037 0.51570.048
p-value o0.0001 o0.0001 o0.0001 o0.0001
Change versus BUD 0.04070.061 – 0.01370.059 –
95% CI 0.159, 0.080 – 0.129, 0.103 –
Spirometry PEF (L/min)
n 270 130 237 120
Baseline 287.3 287.3 286.8 286.8
Change from
baseline
81.375.4 78.377.3 80.475.6 77.177.3
p-value o0.0001 o0.0001 o0.0001 o0.0001
Change versus BUD 3.078.8 – 3.378.9 –
95% CI 14.4, 20.4 – 14.3, 20.9 –
Diary AM PEF (L/min)
n 267 130 245 118
Baseline 371.6 371.6 369.9 369.9
Change from
baseline
8.073.9 4.975.3 8.374.0 6.275.4
p-value 0.0424 NS 0.0400 NS
Change versus BUD 3.176.3 – 2.176.4 –
95% CI 9.4, 15.5 – 10.6, 14.7 –
Diary PM PEF (L/min)
n 267 130 245 119
Baseline 382.0 382.0 380.2 380.2
Change from
baseline
9.074.1 0.175.4 9.274.2 1.275.6
p-value 0.0263 NS 0.0296 NS
Change versus BUD 9.176.5 – 8.076.7 –
95% CI 3.7, 21.9 – 5.2, 21.2 –
All data are presented as LS mean and LS mean7SEM.
ITT, intention to treat; PP, per protocol; FEV1, forced expiratory volume in 1 s; BUD, budesonide; CI, conﬁdence interval; FVC, forced
vital capacity; PEF, peak expiratory ﬂow; AM, morning; PM, evening; NS, non-signiﬁcant; LS, least squares; SEM, standard error of the
mean.
Two-sided p-value for within-treatment differences, signiﬁcance level 5% (study end versus baseline).
Ciclesonide and budesonide in adolescent asthma 2187pressure and heart rate were stable throughout the study
in both treatment groups. Very few patients had abnormal
ECG ﬁndings and none of these ﬁndings were clinically
relevant.Discussion
The current study reports the ﬁrst comparison of the
efﬁcacy and safety of ciclesonide 320 mg once daily and
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Figure 2 Time course of % predicted forced expiratory volume
in 1 s during the treatment period (intention-to-treat popula-
tion). FEV1 forced expiratory volume in 1 s; BUD, budesonide;
CIC, ciclesonide; PM, evening.
J.H. Vermeulen et al.2188budesonide 800 mg once daily exclusively in an adolescent
population with severe asthma. In patients not well
controlled after treatment with budesonide 400 mg once
daily or equivalent for at least 4 weeks prior to study entry
and budesonide 400 mg once daily for the 2-week run-in
period, treatment with ciclesonide 320 mg once daily and
budesonide 800 mg once daily in the evening signiﬁcantly
increased lung function measures. For example, the
increase from baseline in FEV1 was more than 500mL in
both treatment groups, indicating that patients in this study
were not at the top of the dose–response curve prior to
randomization.
In this adolescent population, the non-inferiority of
ciclesonide to budesonide was demonstrated for the primary
variable FEV1, which was further supported by non-
inferiority for FVC and PEF, indicating equipotency of
ciclesonide 320 mg once daily and budesonide 800 mg once
daily. The percentage of days without any asthma symptoms
and without use of rescue medication was also non-inferior
between treatment groups. Assessment of asthma symptom
scores, as well as percentages of asthma symptom-, rescue
medication- and nocturnal awakening-free days, also re-
vealed no statistically signiﬁcant or clinically relevant
differences between the efﬁcacy of ciclesonide and the
higher dose of budesonide.
These ﬁndings are consistent with those from other
studies demonstrating the efﬁcacy of ciclesonide in adults
and children.15–18,20,28–30 In particular, these results are in
line with two previous clinical studies in adults comparing
ciclesonide 320 mg with budesonide 400 mg administered
once daily.28,31 In one study, ciclesonide was numerically
better at improving FEV1.
28 In the other study, ciclesonide
was shown to be signiﬁcantly better than budesonide with
respect to improvements in FEV1 and FVC.
31 Therefore, a
dose of 800 mg budesonide was chosen in this study to
compare with the 320 mg ciclesonide dose. In addition, in the
current patient population, control of asthma was not
optimal during the 2-week run-in period with 400 mgbudesonide once daily or with previous treatment prior to
study entry, justifying the stepup of the budesonide dose to
800 mg once daily during the double-blind treatment period.
Another study comparing twice-daily ﬂuticasone propio-
nate and once-daily ciclesonide showed similar efﬁcacy of
ciclesonide on a microgram basis in improving lung function
and asthma symptoms, and in reducing rescue medication
use in adult patients with asthma.30 Furthermore, two
multicenter, double-blind, double-dummy, randomized,
parallel-group studies investigating the effects of cicleso-
nide and ﬂuticasone propionate in populations including
adolescents with persistent asthma have shown the similar
efﬁcacies of the two agents.32,33 In one study in children
and adolescents aged 6–15 years, ciclesonide 80 mg twice
daily and ﬂuticasone propionate 88 mg twice daily signiﬁ-
cantly improved pulmonary function, with comparable
improvements in both treatment groups.32 Similarly, in the
second study (in adolescent and adult patients aged 12–75
years), ciclesonide 80 or 160 mg once daily and ﬂuticasone
propionate 88 mg twice daily signiﬁcantly improved pulmon-
ary function, as measured by improvement in FEV1.
33 In
both studies, both treatments also signiﬁcantly impro-
ved asthma symptoms and reduced the need for rescue
medication.32,33
Patient QoL assessments are increasingly being recog-
nized as an important outcome measurement in order to
provide a more sensitive and comprehensive approach when
evaluating asthma treatments. In the current study, baseline
values for QoL scores were already high due to run-in
treatment with 400 mg budesonide. Despite limited room for
improvement, both ciclesonide and budesonide signiﬁ-
cantly improved patient QoL to a similar extent. Non-
inferiority of ciclesonide was demonstrated overall and for
the individual domains of activities, symptoms and emo-
tions. The treatment of patients with chronic diseases
during the transition from childhood to adulthood represents
a particular management challenge. Emotional symptoms
related to asthma in this age group are common,34 with
patients often reporting feelings of anxiety, fear and
embarrassment about their asthma.35 Feelings of control
over asthma symptoms are particularly important in this
population and correlate with positive attitudes towards
self-management.35
ICS are often associated with local or systemic AEs, which
are a particular concern for patients with long-term
exposure to high-dose ICS. The ﬁndings of the safety
assessments in the current study showed that both treat-
ments were well tolerated with no relevant changes in
standard laboratory tests, physical examination, ECG re-
cordings or vital signs with either study medication. In terms
of local effects, there were no cases of conﬁrmed
oropharyngeal candidiasis during the study. Similarly, neg-
ligible oropharyngeal AEs with ciclesonide have been
reported previously.18
In the current study, equipotent doses of ciclesonide and
budesonide were evaluated in adolescent patients who were
not well controlled on their previous treatment. However,
budesonide, but not ciclesonide, had a suppressive inﬂuence
on the HPA axis, an indirect measure of systemic exposure,
as indicated by a signiﬁcant decrease in 24-h urine cortisol
levels. The difference between the treatment groups was
signiﬁcant (p ¼ 0.0012). Several other studies have also
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Table 3 Improvement in asthma symptom and quality of life scores after 12 weeks of treatment with either ciclesonide
320 mg once daily or budesonide 800 mg once daily.
Variable ITT PP
Ciclesonide 320 mg once
daily
Budesonide 800 mg once
daily
Ciclesonide 320 mg once
daily
Budesonide 800 mg once
daily
Symptom sum scoresa
n 249 126 222 115
Baseline 0.29 0.29 0.14 0.29
Change from
baseline
0.07 0.14 0.07 0.14
p-value 0.0005 0.0001 0.0020 0.0002
RMU (puffs/day)
n 267 130 245 120
Baseline 0.00 0.14 0.00 0.14
Change from
baseline
0.07 0.07 0.07 0.07
p-value o0.0001 0.0003 0.0001 0.0008
PAQLQ[S] scores
n 262 127 235 116
Overall
Baseline 5.97 5.97 5.99 5.99
Change from
baseline
0.1970.05 0.1870.06 0.1970.05 0.1970.07
p-value 0.0001 0.0056 0.0002 0.0044
Activities
Baseline 5.93 5.93 5.95 5.95
Changes from
baseline
0.2170.05 0.2170.07 0.2170.05 0.2370.07
p-value o0.0001 0.0021 0.0001 0.0011
Symptoms
Baseline 5.84 5.84 5.85 5.85
Change from
baseline
0.1970.05 0.1770.07 0.1870.06 0.1770.08
p-value 0.0007 0.0267 0.0028 0.0254
Emotions
Baseline 6.17 6.17 6.19 6.19
Change from
baseline
0.1870.05 0.1670.06 0.1870.05 0.1870.06
p-value 0.0001 0.0116 0.0002 0.0071
ITT, intention to treat; PP, per protocol; RMU, rescue medication use; PAQLQ, Pediatric Asthma Quality of Life Questionnaire; HL,
Hodges–Lehman; LS, least squares; SEM, standard error of the mean.
aBaseline data are presented as medians and change from data are HL point estimates for asthma symptom scores and RMU. PAQLQ
scores are presented as LS mean and LS mean7SEM.
Two-sided p-value for within-treatment differences, signiﬁcance level 5% (study end versus baseline).
Ciclesonide and budesonide in adolescent asthma 2189shown a lack of effect on the HPA-axis function with
ciclesonide.15,19,36,37 For example, in a study of 164 patients
with mild-to-moderate persistent asthma, ciclesonide
(320 mg once daily and twice daily) had no effect on cortisol
levels following cosyntropin stimulation, whereas signiﬁcant
reductions were observed for ﬂuticasone propionate (400 mg
twice daily) versus placebo.37 The favorable safety and
tolerability proﬁle of ciclesonide reported here may be dueto limited systemic exposure, as ciclesonide and desisobu-
tyryl ciclesonide have a low oral bioavailability, are highly
protein bound and are rapidly metabolized by the
liver.9,11,14,38
In summary, in the current 12-week study, similar
efﬁcacy of ciclesonide 320 mg once daily to budesonide
800 mg once daily was conﬁrmed in adolescents with severe
asthma.
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Figure 3 Symptom-free and rescue medication-free days
during the treatment period (intention-to-treat population).
BUD, budesonide; CIC, ciclesonide; PM, evening.
Table 4 Treatment-emergent adverse events reported
by 42% of patients receiving ciclesonide 320 mg once
daily or budesonide 800 mg once daily (safety set,
n ¼ 403).
Adverse event Frequency of events (% of patients)
Ciclesonide
320 mg once daily
(n ¼ 272)
Budesonide
800 mg once daily
(n ¼ 131)
Total 26.5 18.3
Pharyngitis 5.9 3.8
Asthma aggravated 3.3 1.5
Nasopharyngitis 2.6 0.8
Upper respiratory
tract infection
2.2 2.3
Figure 4 Change in median 24-h urine cortisol adjusted for
creatinine [nmol/mmol] from baseline to study end (restricted
safety set). BUD, budesonide; CIC, ciclesonide; PM, evening.
p ¼ 0.0086 versus baseline to study end; yp ¼ 0.0012 between-
treatment difference.
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